FOURTH AMENDMENT TO LEASELease Agreement • August 7th, 2018 • Karyopharm Therapeutics Inc. • Pharmaceutical preparations
This FOURTH AMENDMENT TO LEASE (this “Amendment”) is dated as of June 6, 2018 (the “Effective Date”) and is hereby entered into by and between AG-JCM Wells Avenue Property Owner, LLC (“Landlord”), a Delaware limited liability company, with an address of c/o Jumbo Capital Management, LLC, 1900 Crown Colony Drive, 4th Floor, Quincy, Massachusetts 02169, and Karyopharm Therapeutics Inc. (“Tenant”), a Delaware corporation, with an address of 85 Wells Avenue, 2nd Floor, Newton, Massachusetts 02459.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omission. LICENSE AGREEMENT by and between KARYOPHARM THERAPEUTICS INC. and ANTENGENE THERAPEUTICS LIMITEDLicense Agreement • August 7th, 2018 • Karyopharm Therapeutics Inc. • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT (this “Agreement”), effective as of May 23, 2018 (the “Effective Date”), is made and entered into by and between Karyopharm Therapeutics Inc., a corporation organized and existing under the laws of the State of Delaware, having an address at 85 Wells Avenue, Suite 210, Newton, MA 02459 USA (“Karyopharm”), and Antengene Therapeutics Limited, a corporation organized and existing under the laws of Hong Kong, having an address at Rm. 19C, Lockhart Ctr., 301-307 Lockhart Rd., Wan Chai, Hong Kong (“Antengene”). Karyopharm and Antengene are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
PARENT COMPANY GUARANTEE For the License Agreement by and between Karyopharm Therapeutics Inc. and Antengene Therapeutics Limited effective as of May 23, 2018 (the “Agreement”)Parent Company Guarantee • August 7th, 2018 • Karyopharm Therapeutics Inc. • Pharmaceutical preparations
Antengene Corporation Co. Ltd., the parent entity of Antengene Therapeutics Limited, hereby fully and irrevocably guarantees the full, complete and punctual performance of all of the obligations of Antengene Therapeutics Limited to Karyopharm Therapeutics Inc. as described in the Agreement, including those financial obligations set forth in Article 8 of the Agreement. A copy of the Agreement is attached hereto as Appendix A.
